Blog

SAN FRANCISCO, CA / ACCESS Newswire / May 21, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (“Jaguar” or “the Company”), today announced that it has entered into definitive agreements for the purchase and sale of 246,306 shares of common stock at a purchase price of $6.09 per share in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company agreed to issue to investors unregistered warrants to purchase up to 492,612 shares of common stock at an exercise price of $5.84 per share that will be immediately exercisable upon issuance and will expire on the earlier of (i) 24 months from the date of issuance, (ii) the consummation of a fundamental transaction and (iii) the consummation of a liquidation event. The closing of the offering is expected to occur on or about May 22, 2025, subject to the satisfaction of customary closing conditions.

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

The gross proceeds to the Company from the offering are expected to be approximately $1.5 million before deducting placement agent fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from the offering for general corporate purposes, including growth capital, working capital, operating expenses, repayment of outstanding convertible promissory notes that are not converted into Common Stock by holders, and capital expenditures.

The common stock (but not the unregistered warrants and the shares of common stock underlying the unregistered warrants) described above are being offered by the Company pursuant to a “shelf” registration statement on Form S-3 (File No. 333-278861) that was declared effective by the Securities and Exchange Commission (the “SEC”) on May 1, 2024. The offering of the shares of common stock is being made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A final prospectus supplement and accompanying prospectus relating to the registered direct offering will be filed with the SEC. Electronic copies of the final prospectus supplement and accompanying prospectus may be obtained, when available, on the SEC’s website at http://www.sec.gov or by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, New York 10022, by phone at (212) 856-5711 or e-mail at placements@hcwco.com.

The unregistered warrants described above are being offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and/or Regulation D promulgated thereunder and, along with the shares of common stock underlying such unregistered warrants, have not been registered under the Securities Act, or applicable state securities laws. Accordingly, the unregistered warrants and underlying shares of common stock may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About the Jaguar Health Family of Companies

Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo’s crofelemer is FDA-approved under the brand name Mytesi^® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar’s Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.

For more information about:

Jaguar Health, visit https://jaguar.health

Napo Pharmaceuticals, visit www.napopharma.com

Napo Therapeutics, visit napotherapeutics.com

Magdalena Biosciences, visit magdalenabiosciences.com

Visit the Make Cancer Less Shitty patient advocacy program on Bluesky, X, Facebook & Instagram

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. These include statements regarding the expected closing of the offering, the intended use of proceeds from the offering, and the Company’s expectations for future development, operations, business strategies and financial performance. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Contact:

hello@jaguar.health
Jaguar-JAGX

SOURCE: Jaguar Health, Inc.

View the original press release on ACCESS Newswire

AUSTIN, TEXAS / ACCESS Newswire / May 21, 2025 / Interactive Strength Inc. (Nasdaq:TRNR) (“TRNR” or the “Company”), maker of innovative specialty fitness equipment under the CLMBR and FORME brands and pending acquirer of Sportstech and Wattbike, today announced that it has updated its investor FAQ’s on its investor website in response to shareholder questions around its AGM date and other corporate actions.

For more commentary, information and details on the rationale for and structure of the expected acquisitions, please see TRNR’s investor presentation on the Company’s investor website as well as its required filings with the US Securities & Exchange Commission (SEC).

TRNR Investor Contact
ir@interactivestrength.com

About Interactive Strength Inc.:

Interactive Strength Inc. produces innovative specialty fitness equipment and digital fitness services under two main brands: 1) CLMBR and 2) FORME. Interactive Strength Inc. is listed on NASDAQ (symbol:TRNR).

CLMBR is a vertical climbing machine that offers an efficient and effective full-body strength and cardio workout. CLMBR’s design is compact and easy to move – making it perfect for commercial or in-home use. With its low impact and ergonomic movement, CLMBR is safe for most ages and levels of ability and can be found at gyms and fitness studios, hotels, and physical therapy facilities, as well as available for consumers at home. www.clmbr.com.

FORME is a digital fitness platform that combines premium smart gyms with live virtual personal training and coaching to deliver an immersive experience and better outcomes for both consumers and trainers. FORME delivers an immersive and dynamic fitness experience through two connected hardware products: 1) The FORME Studio Lift (fitness mirror and cable-based digital resistance) and 2) The FORME Studio (fitness mirror). In addition to the company’s connected fitness hardware products, FORME offers expert personal training and health coaching in different formats and price points through Video On-Demand, Custom Training, and Live 1:1 virtual personal training. www.formelife.com.

Forward Looking Statements:
This press release includes certain statements that are “forward-looking statements” for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements do not relate strictly to historical or current facts and reflect management’s assumptions, views, plans, objectives and projections about the future. Forward-looking statements generally are accompanied by words such as “believe”, “project”, “expect”, “anticipate”, “estimate”, “intend”, “strategy”, “future”, “opportunity”, “plan”, “may”, “should”, “will”, “would”, “will be”, “will continue”, “will likely result” or similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding the possibility of acquiring future businesses or completing the referenced pending transactions in a timely manner or at all, the financial performance of those acquisitions and the resulting guidance of having more than $75m of pro forma revenue in 2025, achieving profitability by Q4, and the financial performance of the acquisition targets which have not been audited or reviewed by a PCAOB auditor and could vary materially (a) once that audit or review work is completed and such financials are included in the Company’s reported financials and (b) due to the effect of the exchange rates of foreign currencies which can be volatile. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of the Company. Risks and uncertainties include but are not limited to: demand for our products; competition, including technological advances made by and new products released by our competitors; our ability to accurately forecast consumer demand for our products and adequately maintain our inventory; and our reliance on a limited number of suppliers and distributors for our products. A further list and descriptions of these risks, uncertainties and other factors can be found in filings with the Securities and Exchange Commission. To the extent permitted under applicable law, the Company assumes no obligation to update any forward-looking statements.

# # #

SOURCE: Interactive Strength Inc.

View the original press release on ACCESS Newswire

NEWARK, CA / ACCESS Newswire / May 21, 2025 / Protagonist Therapeutics, Inc. (“Protagonist” or the “Company”) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will present a company overview at the Jefferies Global Healthcare Conference taking place June 3-5, 2025, in New York, NY. The Company will also participate in one-on-one meetings.

Jefferies Global Healthcare Conference – June 3-5, 2025

Format: Company Presentation
Day/Time: Wednesday, June 4 at 1:25 P.M. ET
Webcast: https://wsw.com/webcast/jeff319/ptgx/1883080

If you are interested in meeting with the Protagonist team during the conference, please reach out to your Jefferies representative.

A replay of the presentation will be available on the Company’s Investor Relations Events and Presentations webpage for one year following the event.

About Protagonist
Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company. Two novel peptides, icotrokinra and rusfertide, derived from Protagonist’s proprietary discovery platform are currently in advanced Phase 3 clinical development, with New Drug Application submissions to the FDA expected in 2025. Icotrokinra (JNJ-2113) is a first-in-class investigational targeted oral peptide that selectively blocks the Interleukin-23 receptor (“IL-23R”) which is licensed to Janssen Biotech, Inc., a Johnson & Johnson company. Following icotrokinra’s joint discovery by Protagonist and Johnson & Johnson scientists pursuant to the companies’ IL-23R collaboration, Protagonist was primarily responsible for development of icotrokinra through Phase 1, with Johnson & Johnson assuming responsibility for development in Phase 2 and beyond. Rusfertide, a mimetic of the natural hormone hepcidin, is currently in Phase 3 development for the rare blood disorder polycythemia vera (PV). Rusfertide is being co-developed and will be co-commercialized with Takeda Pharmaceuticals pursuant to a worldwide collaboration and license agreement entered into in 2024 under which the Company remains primarily responsible for development through NDA filing. The Company also has a number of pre-clinical stage oral drug discovery programs addressing clinically and commercially validated targets, including the IL-17 oral peptide antagonist PN-881, an oral hepcidin program, and an oral obesity program.

More information on Protagonist, its pipeline drug candidates and clinical studies can be found on the Company’s website at www.protagonist-inc.com.

Investor Relations Contact
Corey Davis, Ph.D.
LifeSci Advisors
+1 212 915 2577
cdavis@lifesciadvisors.com

Media Contact
Virginia Amann, Founder/CEO
+1 833 500 0061 ext 1
ENTENTE Network of Companies
virginiaamann@ententeinc.com

SOURCE: Protagonist Therapeutics

View the original press release on ACCESS Newswire

TORONTO, ON / ACCESS Newswire / May 21, 2025 / Grid Metals Corp. (TSXV:GRDM)(OTCQB:MSMGF) (“Grid” or the “Company”) announced drill results from the remaining 19 drill holes at the Eagle gabbro and the completion of new geophysical surveys at the Mayville copper/nickel project in southeastern Manitoba. The drilling confirmed a 2 km mineralized trend at the eastern part of the Mayville Complex. Newly completed airborne geophysics has provided multiple targets for new discoveries and resource expansion.

The next planned Grid drill program in the Bird River area is at the Makwa nickel/copper property. Permitting for exploration drilling is well advanced and an ongoing field program at Makwa is focused on the highest priority geophysical targets from the recently completed Geotech Ltd. VTEM™ MAX electromagnetic survey. The Makwa property is subject to an option and joint venture agreement currently funded by Teck Resources Limited.

The Company is also in the process of permitting exploration drilling at the Falcon West property for cesium. The most recent drilling at the Lucy pegmatite (Q1 2024) by Grid intersected 3.20m of 4.6% Cs₂O in a >100-metre-long cesium-enrichment trend. The drill target at Lucy is a near-surface, flat-lying cesium and lithium-enriched portion of the larger Lucy Pegmatite in which most of the cesium is believed to be associated with the primary cesium ore mineral, pollucite. Pollucite is the preferred feedstock to the cesium chemicals industry, including the nearby Tantalum Mining Corporation of Canada Ltd.’s cesium chemical plant. The next phase of drilling at the Lucy Pegmatite will be designed to test the distribution of pollucite within this specific target area.

Eagle Gabbro Exploration Highlights

• New airborne EM surveys completed in Q4 2024 have defined numerous, strong EM anomalies at the Mayville project that could reflect massive magmatic sulfide accumulations.

Dr. Dave Peck, P.Geo., Grid’s Vice President of Exploration, stated “The new drill results confirm the mineralized nature at the Eagle gabbro, which is located ~10 km from Grid’s existing 32 Mt indicated open-pit, copper-rich Mayville deposit². We are now looking at a ~20 km long mineralized mafic-ultramafic complex having demonstrated potential to expand on the Mayville resource. Moreover, the results from the recent, deep penetrating EM surveys have highlighted the potential for high-grade massive sulfide deposits on the Property. In the future, adding new high-grade resources to the known near-surface disseminated sulfide deposits is seen as the best path forward for this project.”

Figure 1. Location of the 1) Mayville Deposit (yellow); 2) the top-ranked and untested conductor anomalies potentially associated with massive Cu-Ni sulfide mineralization at the Mayville project; and 3) the Eagle gabbro area. The map shows the interpreted limits of the Mayville-Eagle Complex (black outline) on a tilt derivative total magnetic intensity background image.

¹ The Mayville deposit is located ~10 km to the west of the Eagle gabbro and is estimated to contain 32.0 million tonnes of indicated resources averaging 0.40% Cu and 0.16% Ni (see the Company’s May 6, 2024 news release for details)

² Cu Eq is the copper equivalent grade, calculated as follows: CuEq (%) = Cu% + ((Ni% x NiR x NiP) + (Co% x CoR x CoP) + (Pt g/t x PtR x PtP) + (Pd g/t x PdR x PdP) + (Au g/t x AuR x AuP))/(CuR x CuP) where R = metal recovery and P = metal price. The following fixed metallurgical recoveries were assumed, guided by metallurgical test results reported by Micon International in the current Technical Report for the property (June 2024 – see Company website for details): Cu – 85%; Ni and Co – 60%; Pd, Pt and Au – 70%. The following long-term metal prices in US dollar amounts were assumed: Cu – $4.00/lb; Ni – $9.00/lb; Co – $22.50/lb; Pd – $1,100/oz; Pt – $1,100/oz; Au – $2,200/oz.

³ The New Manitoba deposit has a historical resource estimate of 2.0 million short tons averaging 0.75% Cu and 0.33% Ni (Manitoba Mineral Inventory Card #217). The Company has not been able to verify the historical estimate as relevant and the historical estimate should not be relied on.

Figure 2. Hole locations for the Q4 2024 Eagle gabbro drilling program. The map shows the interpreted position of the 4 km-long Eagle gabbro (black dotted outline), which is the host to the New Manitoba deposit, on a tilt derivative total magnetic intensity background image. Magnetic high anomalies are indicated by warmer colours.

Drill Program and Detailed Results
A total of 4,132 metres were drilled in 25 holes during the Q4 2024 drill program at the Eagle gabbro (Figure 1). Three discrete targets were tested along a ~2 km segment of the Eagle gabbro. These included 11 holes targeting the historical New Manitoba deposit in the south (holes EAG24-01 to 11); 4 holes at a linear magnetic anomaly located ~500m north of the New Manitoba deposit (‘E15’ target; holes EAG24-13, 14, 16 and 17); and 6 holes at a previously untested disseminated sulfide occurrence at the Acme target area, located 1.2 km north of E15 (holes EAG24-20-25). Two holes were drilled on a conductor (EAG24-016) and a flanking magnetic anomaly (EAG24-17) located ~1 km east of the Eagle gabbro. One hole tested an unmapped magnetic anomaly located along the east side of the Eagle gabbro (EAG24-12). One hole was abandoned (EAG24-15).

All but one of the holes that intersected the Eagle gabbro encountered a steeply-dipping, several metre- to ~40-metre-thick interval of Cu-rich disseminated sulfide mineralization (the ‘Eagle Cu Zone’). The average grades and metal tenors for the Eagle Cu Zone closely resemble those characterizing the Mayville deposit. Most of these new drill intersections are shallow (

Table 1. Highlights for the Q4 2024 Eagle drilling program. The true thickness of the drill intersections reported here are estimated to represent 40 – 90% of the interval lengths. Results for drill holes EAG24-01 to 06 were previously reported (see the Company’s Dec. 2, 2024 news release).

	From (m)	To (m)	Interval (m)	Cu (%)	Ni (%)	Co (%)	Pd (g/t)	Pt (g/t)	Au (g/t)	S (%)	Cu Eq (%)	Target Area
EAG24-01	45.50	87.15	41.65	0.35	0.10	0.01	0.05	0.01	0.03	1.44	0.58	E15
inc.	63.75	79.00	15.25	0.65	0.11	0.01	0.07	0.02	0.05	1.87	0.92
with	75.90	77.00	1.10	3.43	0.11	0.01	0.01	0.00	0.09	4.53	3.70
and inc.	86.50	87.15	0.65	0.30	1.40	0.07	0.43	0.06	0.01	17.9	2.95
EAG24-02	53.00	90.00	37.00	0.41	0.12	0.01	0.06	0.02	0.04	1.69	0.69	E15
inc.	69.00	89.00	20.00	0.61	0.16	0.01	0.08	0.03	0.06	2.46	0.99
EAG24-03	56.00	93.90	37.90	0.38	0.17	0.01	0.07	0.02	0.03	2.46	0.74	New Manitoba
inc.	82.00	88.00	6.00	0.49	0.45	0.03	0.11	0.04	0.04	7.03	1.41
with	86.35	87.05	0.70	0.28	1.28	0.09	0.21	0.12	0.07	18.77	2.81
EAG24-04	62.00	82.00	20.00	0.45	0.21	0.02	0.05	0.02	0.03	3.36	0.90	New Manitoba
inc.	69.00	73.00	4.00	0.87	0.58	0.04	0.06	0.03	0.05	9.20	2.03
EAG24-05	55.00	101.0	46.00	0.58	0.15	0.01	0.09	0.03	0.05	2.79	0.95	New Manitoba
inc.	71.55	98.00	26.45	0.78	0.16	0.01	0.13	0.05	0.07	3.03	1.19
EAG24-06	50.00	94.30	44.30	0.46	0.21	0.02	0.09	0.03	0.04	3.03	0.93	New Manitoba
inc.	63.00	88.00	25.00	0.72	0.35	0.03	0.13	0.05	0.05	5.05	1.47
with	71.25	86.00	14.75	0.87	0.47	0.03	0.16	0.06	0.06	6.43	1.86
and inc.	71.25	72.00	0.75	0.20	2.37	0.16	0.58	0.38	0.01	9.44	4.92
EAG24-07	105.2	176.0	70.8	0.49	0.15	0.01	0.08	0.03	0.05	2.36	0.85	New Manitoba
inc.	106.0	139.6	33.6	0.69	0.21	0.02	0.13	0.05	0.08	3.47	1.20
with	111.0	124.8	13.8	0.90	0.25	0.02	0.16	0.06	0.10	4.27	1.50
EAG24-09	149.6	158.5	8.90	0.63	0.11	0.01	0.07	0.02	0.03	2.05	0.90	New Manitoba
EAG24-10	86.00	102.2	16.25	0.57	0.21	0.02	0.09	0.03	0.05	3.60	1.04	New Manitoba
EAG24-16	145.0	181.0	36.00	0.37	0.12	0.01	0.06	0.02	0.03	1.51	0.66	E15
inc.	160.2	180.0	19.75	0.48	0.15	0.01	0.08	0.02	0.04	1.85	0.82
EAG24-17	172.0	194.3	22.30	0.41	0.15	0.01	0.03	0.07	0.02	1.90	0.75	E15
inc.	173.0	182.0	9.00	0.53	0.17	0.01	0.05	0.08	0.03	2.18	0.91
EAG24-21	74.00	77.00	3.00	0.56	0.15	0.01	0.10	0.03	0.05	1.40	0.92	Acme
inc.	91.00	97.75	6.75	0.43	0.10	0.01	0.07	0.03	0.09	0.93	0.70
EAG24-22	84.45	105.0	20.55	0.27	0.08	0.01	0.04	0.02	0.11	1.16	0.52	Acme
inc.	84.45	91.00	6.55	0.56	0.15	0.01	0.09	0.03	0.30	1.66	1.07
EAG24-23	114.0	118.2	4.20	0.42	0.13	0.01	0.06	0.02	0.05	1.23	0.72	Acme

Geophysical Surveys
Two new airborne EM surveys were completed during the fall and winter of 2024 at the Mayville project area. Geotech Ltd. completed a 143 line km time domain VTEM™ MAX survey over a 3.3 by 4.5 km area at a nominal line spacing of 100 metres and covering the Eagle gabbro in the eastern part of the project area. Geotech also completed a 258 line km deep-penetrating frequency domain EM survey over an 6.8 by 10.4 km area at a nominal 300 metre line spacing covering the central and eastern part of the Mayville-Eagle project area using their proprietary heli-borne ZTEM™ system. Preliminary modeling of the new survey results has identified several strongly conductive anomalies coincident with mapped or interpreted (from magnetics) parts of the 20 km long Mayville-Eagle Complex and with interpreted northeast-striking feeder structures to the complex.

A 5-line pole-dipole IP survey was also completed during the past winter over an area of ~800 metres x 900 metres that covers the historical New Manitoba deposit. The results of the survey highlight a large chargeability anomaly associated with the deposit but extending east and north beyond the known limits of the deposit. The new results highlight an opportunity to expand the historical resources estimated at New Manitoba.

Quality Assurance and Quality Control
Grid Metals applies best practice quality assurance and quality control (“QAQC”) protocols in all of its exploration programs. For the current Eagle drilling program, core was logged and sampled at the Company’s core facility located on the Makwa property. Standard 1.0 metre sample lengths were used. Samples were bagged and tagged and then transported by secure carrier to the Actlabs (Thunder Bay) laboratory for sample preparation and analysis for nickel, copper, cobalt and selected major and trace element abundances using a multi-acid digestion method followed by ICP-OES analysis. Samples were also analyzed for Pd, Pt and Au using a lead collection 30 g fire assay method followed by ICP-OES analysis. The Company is using several different certified reference materials (“CRMs”) and one analytical blank for the Makwa program to monitor analytical accuracy and check for cross contamination between samples. The analytical results for the CRMs and the blank for the new analytical results reported here did not show any significant bias compared to the certified values and the fell within the acceptable limits of variability.

For more information about the Company, please see the Company website at www.gridmetalscorp.com or contact:

Robin Dunbar – President, CEO & Director Telephone: 416-955-4773 Email: rd@gridmetalscorp.com
Brandon Smith – Chief Development Officer – bsmith@gridmetalscorp.com
David Black – Investor Relations Email – info@gridmetalscorp.com

Qualified Persons Statements
Dr. Dave Peck, P.Geo., the VP Exploration of Grid, is the Qualified Person for purposes of National Instrument 43-101 and has reviewed and approved the technical content of this release.

About Grid Metals Corp.
Grid Metals is focused on exploration and development in southeastern Manitoba with four key projects in the Bird River area.

1. The Makwa Property (Ni-Cu-PGM-Co), which is subject to an Option and Joint Venture Agreement with Teck Resources Limited (“Teck”). Teck can earn up to a 70% interest in Makwa by incurring a total of CAD$17.3 million, comprising project expenditures (CAD$15.7 million) and cash payments or equity participation (CAD$1.6 million) with Grid. Makwa is located on the south arm of the Bird River Greenstone Belt.

2. The Mayville Property (Cu-Ni) is located on the north arm of the Bird River Greenstone Belt. The property is owned subject to a minority interest.

3. The Donner Property (Li-Cs) is adjacent to the Mayville Property, and Grid owns 75% of the project. Grid announced a cesium purchase agreement with Tanco on February 18, 2025.

4. The Falcon West Property (Li-Cs) is located 110 km east of Winnipeg along the Trans-Canada highway and contains highly anomalous cesium values in a number of historical drill holes including 2.2 m at 15.0% Cs₂O and 3.2 m at 4.6% Cs₂O.

All of the Company’s southeastern Manitoba projects are located on the ancestral lands of the Sagkeeng First Nation with whom the Company maintains an Exploration Agreement.

We seek safe harbour. This news release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 and forward-looking information within the meaning of the Securities Act (Ontario) (together, “forward-looking statements”). Such forward-looking statements include the Company’s closing of the proposed financial transactions, sale of royalty and property interests. the overall economic potential of its properties, the availability of adequate financing and involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements expressed or implied by such forward-looking statements to be materially different. Such factors include, among others, risks and uncertainties relating to potential political risk, uncertainty of production and capital costs estimates and the potential for unexpected costs and expenses, physical risks inherent in mining operations, metallurgical risk, currency fluctuations, fluctuations in the price of nickel, cobalt, copper and other metals, completion of economic evaluations, changes in project parameters as plans continue to be refined, the inability or failure to obtain adequate financing on a timely basis, and other risks and uncertainties, including those described in the Company’s Management Discussion and Analysis for the most recent financial period and Material Change Reports filed with the Canadian Securities Administrators and available at www.sedar.com.

Neither the TSX Venture Exchange nor its Regulations Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Appendix: Drill hole specifications for all holes completed during the Q4 2024 Eagle gabbro drilling program. Collar coordinates are based on a NAD83 UTM Zone 15N projection.

Hole ID	Target	Easting	Northing	Azimuth	Dip	Elevation (m)	Length (m)
EAG24-01	E15	324019	5609052	45	-45	310	159
EAG24-02	E15	324019	5609052	90	-45	310	174
EAG24-03	New Manitoba	324361	5608676	45	-45	315	150
EAG24-04	New Manitoba	324361	5608676	45	-60	315	150
EAG24-05	New Manitoba	324383	5608658	45	-60	316	153
EAG24-06	New Manitoba	324383	5608658	45	-45	316	150
EAG24-07	New Manitoba	324450	5608753	190	-45	316	186
EAG24-08	New Manitoba	324489	5608583	7	-60	314	150
EAG24-09	New Manitoba	324400	5608614	80	-45	314	174
EAG24-10	New Manitoba	324338	5608698	45	-45	314	120
EAG24-11	New Manitoba	324338	5608698	15	-45	314	150
EAG24-12	E15	324265	5608908	40	-45	314	150
EAG24-13	E15	324060	5609010	45	-45	314	151
EAG24-14	E15	323926	5609134	45	-45	314	150
EAG24-15	E15 (abandoned)	323926	5609134	45	-60	314	9
EAG24-16	E15	323926	5609134	90	-45	314	205
EAG24-17	E15	323926	5609134	90	-60	314	213
EAG24-18	EM Anomaly	324854	5609767	210	-50	326	180
EAG24-19	Mag Anomaly	324854	5609767	45	-45	326	120
EAG24-20	Acme	323595	5610143	45	-45	216	216
EAG24-21	Acme	323668	5610351	225	-45	318	213
EAG24-22	Acme	323589	5610269	45	-45	318	174
EAG24-23	Acme	323553	5610327	0	-45	318	201
EAG24-24	Acme	323433	5610397	45	-45	318	180
EAG24-25	Acme	323564	5610248	225	-45	318	249

SOURCE: Grid Metals Corp.

View the original press release on ACCESS Newswire

100>

Company successfully completes major equipment and process flow testing for the commercial design of its large-scale boron facility

5E’s project advancements positions the United States to maintain position of strength in the global boron supply chain and disrupt the global boron market oligopoly

HESPERIA, CA / ACCESS Newswire / May 21, 2025 / 5E Advanced Materials, Inc. (Nasdaq:FEAM)(ASX:5EA) (“5E” or the “Company”), a boron and lithium company with U.S. government Critical Infrastructure designation for its 5E Boron Americas Complex, today announced that it has achieved another developmental milestone, completing equipment testing for all major processes of the commercial design for its large-scale boron facility. This disciplined approach now enables 5E to focus and transition the team’s efforts towards updating the Company’s technical report summary in the near term.

“Over the past three months, 5E and our EPC-partner Fluor have coordinated with various equipment manufacturers, third-party laboratories and our Small-Scale Facility team to test various aspects of our commercial design,” stated Paul Weibel, Chief Executive Officer. “The testing has included crystallization, metal impurity removal, centrifuges, filtration, reverse osmosis, membrane technology, and dryer packages. As expected, our testing was highly successful and the results of which now position the Company to update our technical report summary and initiate a smooth transition to FEED engineering. We believe the successful testing at this phase in the process will carry significant merit during our project financing diligence as we position the Company to break up the global boron market’s oligopoly. Our success will ensure that the United States no longer has a single point of supply chain failure and maintains a position of strength in the global boron market.”

About 5E Advanced Materials, Inc.

5E Advanced Materials, Inc. (NASDAQ: FEAM) (ASX:5EA) is focused on becoming a vertically integrated global leader and supplier of boron specialty and advanced materials, complemented by lithium co-product production. The Company’s mission is to become a supplier of these critical materials to industries addressing global decarbonization, food and domestic security. Boron and lithium products will target applications in the fields of electric transportation, clean energy infrastructure, such as solar and wind power, fertilizers, and domestic security. The business strategy and objectives are to develop capabilities ranging from upstream extraction and product sales of boric acid, lithium carbonate and potentially other co-products, to downstream boron advanced material processing and development. The business is based on our large domestic boron and lithium resource, which is located in Southern California and designated as Critical Infrastructure by the Department of Homeland Security’s Cybersecurity and Infrastructure Security Agency.

Forward Looking Statements

This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. All statements other than statements of historical fact included in this press release regarding the Company’s business strategy, plans, goals, and objectives, including regarding the expected closing date of the private placement transaction and the anticipated benefits of the private placement transaction, are forward-looking statements. When used in this press release, the words “believe,” “project,” “expect,” “forecast,” “anticipate,” “estimate,” “intend,” “seek,” “budget,” “target,” “aim,” “strategy,” “plan,” “guidance,” “outlook,” “intent,” “may,” “should,” “could,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. These forward-looking statements are based on the Company’s current expectations and assumptions about future events and are based on currently available information as to the outcome and timing of future events. We caution you that these forward-looking statements are subject to all of the risks and uncertainties, most of which are difficult to predict and many of which are beyond our control, incident to the extraction of the critical materials we intend to produce and advanced materials production and development. These risks include, but are not limited to: our limited operating history in the borates and lithium industries and no revenue from our proposed extraction operations at our properties; our need for substantial additional financing to continue as a going concern and to execute our business plan and our ability to access capital and the financial markets; our status as an exploration stage company dependent on a single project with no known Regulation S-K 1300 mineral reserves and the inherent uncertainty in estimates of mineral resources; our lack of history in mineral production and the significant risks associated with achieving our business strategies, including our downstream processing ambitions; our incurrence of significant net operating losses to date and plans to incur continued losses for the foreseeable future; risks and uncertainties relating to the development of the Fort Cady project, including our ability to timely and successfully complete our proposed Commercial Scale Boron Facility, and related matters on a timely manner or at all; our ability to obtain, maintain and renew required governmental permits for our development activities, including satisfying all mandated conditions to any such permits; the implementation of and expected benefits from certain reduced spending measures; and other risks and uncertainties set forth in our filings with the U.S. Securities and Exchange Commission from time to time. Should one or more of these risks or uncertainties occur, or should underlying assumptions prove incorrect, our actual results and plans could differ materially from those expressed in any forward-looking statements. These risks are not exhaustive and the information in this press release may be subject to additional risks. No representation or warranty (express or implied) is made as to, and no reliance should be placed on, any information, including projections, estimates, targets, and opinions contained herein, and no liability whatsoever is accepted as to any errors, omissions, or misstatements contained herein. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as to the date of this press release.

For additional information regarding these various factors, you should carefully review the risk factors and other disclosures in the Company’s Form 10-K filed on September 9, 2024 and subsequent filings with the U.S. Securities and Exchange Commission, as well as in its filings under the Australian Securities Exchange. Any forward-looking statements are given only as of the date hereof. Except as required by law, 5E expressly disclaims any obligation to update or revise any such forward-looking statements. Additionally, 5E undertakes no obligation to comment on third party analyses or statements regarding 5E’s actual or expected financial or operating results or its securities.

For further information contact:

Nathan Skown or Joseph Caminiti
Alpha IR Group
FEAM@alpha-ir.com
Ph: +1 (312) 445-2870

SOURCE: 5E Advanced Materials, Inc.

View the original press release on ACCESS Newswire

CAMBRIDGE, MA / ACCESS Newswire / May 21, 2025 / Moderna, Inc. (Nasdaq:MRNA), today announced that in consultation with the U.S. Food and Drug Administration (FDA), the Company has voluntarily withdrawn the pending Biologics License Application (BLA) for mRNA-1083, its flu/COVID combination vaccine candidate for adults aged 50 years and older. The Company plans to resubmit the BLA later this year, after vaccine efficacy data from the ongoing Phase 3 trial of its investigational seasonal influenza vaccine, mRNA-1010, are available. Moderna continues to expect interim data from the mRNA-1010 trial to be available this summer.

About Moderna

Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.

Moderna’s mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the withdrawal of the BLA for mRNA-1083, plans for future resubmission of the mRNa-1083 BLA, and anticipated timing for efficacy data for Moderna’s seasonal flu vaccine candidate, mRNA-1010. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading “Risk Factors” in Moderna’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and in subsequent filings made by Moderna with the U.S. Securities and Exchange Commission, which are available on the SEC’s website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date of this press release.

Moderna Contacts

Media:
Chris Ridley
Global Head of Media Relations
+1 617-800-3651
Chris.Ridley@modernatx.com

Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
+1 617-209-5834
Lavina.Talukdar@modernatx.com

SOURCE: Moderna, Inc.

View the original press release on ACCESS Newswire

As announced, initial proof-of-concept (POC) results from distinct ongoing investigator-initiated trial (IIT) in Abu Dhabi show crofelemer reduced total parenteral support in a pediatric MVID patient with intestinal failure by up to 27%; per the IIT protocol, patient was taken off crofelemer after 12 weeks of treatment for a period of 30 days, but was restarted on daily crofelemer treatment after just 8 days, as patient’s symptoms were worsening

Additional POC IIT results expected throughout 2025 for MVID; results from company’s MVID Phase 2 study expected with completion of treatment in H2 2026

Ground-breaking results in single-digit number of MVID patients could potentially lead to expedited approval in the EU through PRIME and to Breakthrough Therapy designation in the US

SAN FRANCISCO, CA / ACCESS Newswire / May 20, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family companies Napo Pharmaceuticals, Inc. (Napo) and Napo Therapeutics S.p.A. today announced that the first patient has been randomized in Napo’s randomized, double-blind, placebo-controlled Phase 2 clinical trial to evaluate the safety and efficacy of the novel crofelemer oral powder for solution formulation in pediatric patients with intestinal failure due to the ultrarare disease MVID.

Patients with MVID suffer from devastating diarrhea and dehydration caused by this debilitating, lifelong condition. These pediatric patients often require lifelong and life-sustaining total parenteral nutrition (TPN) with additional supplemental intravenous (IV) fluids, termed total parenteral support, which is the standard of care for MVID, for up to 7 days a week greater than 50% of the time each day to provide adequate nutrient and electrolyte support. While crucial for MVID patients, TPN carries a significant risk of morbidity and mortality due to infections, metabolic complications, liver and/or kidney disease, and a risk of neurodevelopmental delay. There are currently no approved drug treatments for MVID.

As previously announced, and as presented last month at the 11^th Annual ELITE PED-GI Congress in Abu Dhabi in the United Arab Emirates, the initial proof-of-concept results from the ongoing and independent proof-of-concept investigator-initiated trial (IIT) at Sheikh Khalifa Medical City (SKMC) showed that crofelemer reduced the required TPN and/or supplementary intravenous fluids – collectively referred to as parenteral support – in the first participating MVID patient by up to 27% at the end of 12-weeks of crofelemer treatment. In addition, this data showed that crofelemer reduced stool volume output and/or frequency of watery stools, and increased urine output – an indicator of improved nutrient oral absorption.

Per the protocol for the IIT at SKMC, the pediatric MVID patient was taken off crofelemer after 12 weeks of treatment for a period of 30 days. After just 8 days, the patient’s parents requested reinitiation of crofelemer dosing, as the patient’s symptoms were worsening – evidenced by increased stool output and decreased urine output. Hence, the patient was restarted on daily treatment with crofelemer.

“We’re very happy that the first patient has been randomized in Napo’s randomized, double-blind placebo-controlled Phase 2 clinical trial of crofelemer in pediatric MVID patients,” said Lisa Conte, Jaguar’s founder, president, and CEO. “This is another important milestone in development efforts for crofelemer for the treatment and management of intestinal failure related to this devastating ultrarare pediatric disease. For this study, randomization represents the key milestone of assigning a participating patient to either the crofelemer or placebo treatment group in a double-blind, placebo-controlled within-patient crossover study.”

“Additional proof-of-concept results for MVID from the ongoing IIT of crofelemer at SKMC in pediatric patients with intestinal failure due to MVID and other disorders are expected throughout 2025,” Conte said. “The results of Napo’s randomized double-blind, placebo-controlled Phase 2 study of crofelemer in pediatric MVID patients are expected to be available in the second half of 2026. Because the IIT of crofelemer for MVID is an unblinded, open-label study, results from this IIT are expected to be available sooner.”

Based on the initial proof-of-concept findings presented last month at the 11^th Annual ELITE PED-GI Congress, crofelemer’s novel antisecretory mechanism of action appears to have the potential to provide a novel therapeutic option to modify the disease progression associated with intestinal failure due to MVID in pediatric patients, as evidenced by the reductions in total parenteral support and potential to improve the quality of life of MVID patients.

“Based on preliminary communications with European Medicines Agency (EMA) regulatory members that focus on PRIME (Priority Medicines), a program that provides enhanced interactions and early dialogue for development of novel medicines targeting unmet medical needs, we are excited by the initial findings from the IIT being conducted at SKMC,” said Conte. “We are not aware of any other intervention that has shown the ability to reduce the required administration of life-sustaining parenteral support including TPN, thus potentially improving nutrient absorption in patients with MVID. Given the ultrarare nature of MVID, even a small number of MVID patients showing benefit with crofelemer may allow Napo to explore pathways for expedited regulatory approval in the European Union. Crofelemer may qualify for participation in PRIME in the European Union for MVID and potentially in the U.S. Food and Drug Administration’s (FDA) Breakthrough Therapy program for this ultrarare pediatric indication. Additionally, in accordance with the guidelines of specific EU countries, published data from clinical investigations in MVID could support reimbursed early patient access to crofelemer for this debilitating condition.”

About Crofelemer

Crofelemer is a novel, oral plant-based prescription medicine purified from the red bark sap, also referred to as “dragon’s blood,” of the Croton lechleri tree in the Amazon Rainforest. Napo has established a sustainable harvesting program, under fair trade practices, for crofelemer to ensure a high degree of quality, ecological integrity, and support for indigenous communities.

About the Jaguar Health Family of Companies

Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo’s crofelemer is FDA-approved under the brand name Mytesi^® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar’s Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.

For more information about:

Jaguar Health, visit https://jaguar.health
Napo Pharmaceuticals, visit www.napopharma.com
Napo Therapeutics, visit napotherapeutics.com
Magdalena Biosciences, visit magdalenabiosciences.com

Visit the Make Cancer Less Shitty patient advocacy program on Bluesky, X, Facebook & Instagram

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements.” These include statements regarding Jaguar’s expectation that additional POC results for MVID from the IIT in pediatric patients with intestinal failure due to MVID and other disorders may be available throughout 2025, Jaguar’s expectation that results from the company’s MVID Phase 2 study will be available with completion of treatment in H2 2026, Jaguar’s expectation that crofelemer’s novel antisecretory mechanism of action may have the potential to provide a novel therapeutic option to modify the disease progression associated with intestinal failure due to MVID in pediatric patients and the potential to improve the quality of life of MVID patients, Jaguar’s expectation that, given the ultrarare nature of MVID, even a small number of MVID patients showing benefit with crofelemer may allow Napo to explore pathways for expedited regulatory approval in the Europe Union, Jaguar’s expectation that crofelemer may qualify for participation in PRIME in the European Union for MVID and potentially in the FDA’s Breakthrough Therapyprogram, and Jaguar’s expectation that, in accordance with the guidelines of specific EU countries, published data from clinical investigations in MVID could support reimbursed early patient access to crofelemer for this debilitating condition. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Contact:

hello@jaguar.health
Jaguar-JAGX

SOURCE: Jaguar Health, Inc.

View the original press release on ACCESS Newswire

New ISOLED-D™ line delivers premium, scalable deuterated reagents for OLED synthesis, supporting the industry from R&D through commercial production with CIL’s global manufacturing and expertise.

TEWKSBURY, MASSACHUSETTS / ACCESS Newswire / May 20, 2025 / Cambridge Isotope Laboratories, Inc. (CIL), the global leader in stable isotope-labeled products, announces the launch of ISOLED-D™, a groundbreaking line of deuterated reagents specifically designed for organic light-emitting diode (OLED) synthesis.

ISOLED-D represents a significant advancement in OLED manufacturing technology, offering high-quality deuterated reagents with manufacturing in state-of-the-art, strategically located worldwide facilities. The product line caters to various production scales, from gram quantities for research and development to metric-ton volumes for full-scale commercial manufacturing.

“ISOLED-D demonstrates our commitment to advancing OLED technology through innovative isotope-labeled solutions,” said Tasha Agreste, Business Development Manager for Deuterated Reagents at CIL. “Our ability to scale production from laboratory to industrial quantities positions us as a crucial partner in the OLED manufacturing ecosystem.”

The company’s flexible approach enables seamless collaboration with research and development teams through to commercial production, ensuring consistent quality and reliable supply chains for manufacturers in the rapidly growing OLED market.

Key features of ISOLED-D:

• Premium-grade deuterated reagents for OLED synthesis

• Scalable production capabilities from grams to metric tons

• Manufacturing in state-of-the-art facilities

• Complete R&D to commercialization support

• Backed by CIL’s industry-leading expertise in stable isotope-labeled products

• Deuterated Benzene Recovery program

For more information about ISOLED-D and CIL’s complete range of isotope-labeled products, visit isotope.com.

Contact Information

Crissy Krisko
crissyk@isotope.com
1.978.269.1930

SOURCE: Cambridge Isotope Laboratories, Inc.

Related Images

View the original press release on ACCESS Newswire

LAS VEGAS, NV / ACCESS Newswire / May 20, 2025 / Avant Technologies Inc. (OTCQB:AVAI) (“Avant” or the “Company”), and its JV partner, Ainnova Tech, Inc., (Ainnova), a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI), today announced the companies are in talks with an international healthcare innovation company to license or potentially acquire its patented early disease detection technology. If successful, it’s a global license or acquisition that has the potential to revolutionize preventive health reporting and to generate correlations for future detection of new diseases without the need for all the patient’s data.

Avant and Ainnova continue to grow the footprint and capabilities of their technology portfolio with the goal of being a leader in early disease detection using the Company’s signature AI-driven Vision AI technology platform.

Vinicio Vargas, Chief Executive Officer at Ainnova and member of the Board of Directors of the joint venture company, Ai-nova Acquisition Corp., said of the Company’s aim to continue to add to its portfolio, “Our purpose is to create the future of early disease detection in an accessible way, so that patients can get a preventive check-up anywhere, at a low cost, and easily. We want to prevent patients with risk factors from developing other diseases that could have been avoided before they became a real problem.

“To this end, we are seeking to integrate new technologies into our portfolio within a single platform, both through our R&D efforts and through potential exclusive licenses or acquisitions.”

Avant and Ainnova see the retina as a new vital sign, but also understand that leveraging the results of laboratory tests and basic patient data can all work in concert to provide a comprehensive health report.

Vargas added, “We have already integrated an exclusive license for four algorithms into our Vision AI platform, and we are now in talks to license and potentially acquire an innovative technology that would be a game changer in our industry.”

Avant will inform its shareholders of any updates at an appropriate time.

About Ainnova Tech, Inc.

Ainnova is a Nevada-based healthtech startup with headquarters in San Jose, Costa Rica, and Houston, Texas. Founded by an experienced and innovative team that is dedicated to leveraging artificial intelligence for early disease detection. Recognized with multiple global awards and renowned partnerships with hospitals and medical device companies, we proudly introduce Vision AI – our cutting-edge platform designed to prevent blindness and detect the early onset of diabetes. Explore how Ainnova is revolutionizing healthcare through advanced technology and proactive solutions.

About Avant Technologies Inc.

Avant Technologies, Inc. is an emerging technology company developing solutions in artificial intelligence in healthcare. With a focus on pushing the boundaries of what is possible in AI and machine learning, Avant serves a diverse range of industries, driving progress and efficiency through state-of-the-art technology.

More information about Avant can be found at https://avanttechnologies.com

You can also follow us on social media at:

https://twitter.com/AvantTechAI

https://linkedin.com/company/avant-technologies-ai

https://www.facebook.com/AvantTechAI

https://www.youtube.com/@AvantTechAI

Forward-Looking Statements

Certain statements contained in this press release may constitute “forward-looking statements.” Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company’s ability to raise capital on acceptable terms, if at all, the Company’s successful development of its products and the integration into its existing products and the commercial acceptance of the Company’s products. The forward-looking statements included in this press release represent the Company’s views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date after the date of the press release.

Contact:

Avant Technologies Inc.
info@avanttechnologies.com

SOURCE: Avant Technologies

View the original press release on ACCESS Newswire

Putting People First: The Nation’s Top Research Recruiter Reinforces Its Human-Centric Mission

LOS ANGELES, CA / ACCESS Newswire / May 20, 2025 / Nelson Recruiting, the leading market research recruitment firm in the United States, is taking a bold stance against AI-driven competitors with its latest rebrand and new digital experience. The launch of NelsonRecruiting.com is a bold statement for the 45-year-old organization, reinforcing its human-centric approach to recruiting.

“Our rebrand isn’t just a fresh look – it’s a sharpened statement of who we are and what we believe,” said Steve Nelson, President of Nelson Recruiting. “While AI tools flood the marketplace, we’re doubling down on the human element because we know it drives the most impactful research, the most trusted products, and the best ideas. This evolution sets the stage for our next chapter.”

In an era when companies race to automate and replace human experience with artificial intelligence, Nelson Recruiting is leaning into the one thing technology cannot replace – the voices, motivations, and unbiased feedback of real people. As a trusted recruitment partner for organizations including Harvard Kennedy School’s Institute of Politics “Voices Across America,” Nelson Recruiting is a veteran in research recruitment, and their new digital experience leans into the human angle of data.

The company’s refreshed identity and expanded digital presence position it to meet the growing demand for diverse, high-quality human input at a time when surface-level data alone is no longer enough.

Rebrand Highlights

• Striking New Visual Identity: A modern, confident look welcomes younger generations to participate in market research with approachable, user-friendly resources.

• Enhanced Digital Experience: The redesigned NelsonRecruiting.com makes it faster and easier for clients to explore services, connect with the recruitment team, and launch research projects.

• Inclusive Recruiting & Expanded Reach: Broader reach into hard-to-access demographics, diverse populations, and hybrid methodologies.

• Reinforced Commitment to Diversity: Elevating underrepresented voices and ensuring richer, more inclusive research outcomes.

As industries navigate the balance between automation and knowledge, Nelson Recruiting stands apart as a champion of the human voice. By delivering genuine human insight, the company offers what automation can’t: deep, meaningful understanding that drives more innovative, effective strategies for organizations.

About Nelson Recruiting

Founded in 1980, Nelson Recruiting is a premier market research recruiting firm that delivers expert participant recruitment for projects nationwide. With decades of experience, a reputation for precision and reliability, and a client roster that spans Fortune 500 companies, leading research agencies, and academic institutions, Nelson Recruiting powers the insights behind tomorrow’s innovations. Visit www.NelsonRecruiting.com.

Press contact:

Cobb Rogers
(310) 890-8310
cobb@cyrogers.com

SOURCE: Nelson Recruiting

View the original press release on ACCESS Newswire